Novanta Announces Financial Results for the Fourth Quarter and Full Year 2021

• Full Year 2021 GAAP Revenue of $707 million
• Full Year 2021 GAAP Net Income of $50 million
• Full Year 2021 GAAP Diluted Earnings Per Share of $1.41
• Full Year 2021 Adjusted Earnings Per Share of $2.62
• Full Year 2021 Adjusted EBITDA of $153 million

BEDFORD, Mass.–(BUSINESS WIRE)–Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and full year 2021.

*Reconciliations of GAAP to non-GAAP financial measures, as well as definitions for the non-GAAP financial measures included in this press release and the reasons for their use, are presented below.

“Novanta demonstrated excellent performance in the fourth quarter, with strong double-digit growth for sales, bookings, and profit,” said Matthijs Glastra, Chairperson and Chief Executive Officer of Novanta. “Customer demand continued to be robust in advanced industrial and medical applications, and our customer orders were up 92% year over year, giving us a 1.55 book-to-bill in the fourth quarter and a record level of backlog at the end of the year, at $569 million. We continue to see excellent performance from the new ATI and IMS acquisitions, strong demand generation from our innovation, and continued robust market demand. This performance gives us optimism as we enter the new year, even as we navigate the near-term disruptions caused by the global supply chain shortages, widespread cost inflation, and geopolitical uncertainty.”

Fourth Quarter

During the fourth quarter of 2021, Novanta generated GAAP revenue of $199.0 million, an increase of $51.5 million, or 34.9%, versus the fourth quarter of 2020. The Company’s acquisition activities resulted in an increase in revenue of $32.1 million, or 21.8%, compared to the fourth quarter of 2020. Changes in foreign currency exchange rates year over year adversely impacted our revenue by $1.3 million, or 0.9%, during the fourth quarter of 2021. Our year-over-year Organic Revenue Growth, which excludes the net impact of acquisitions and changes in foreign currency exchange rates, was an increase of 14.0% for the fourth quarter of 2021 (see “Organic Revenue Growth” in Reconciliation of GAAP to Non-GAAP Financial Measures below).

In the fourth quarter of 2021, GAAP operating income was $21.7 million, compared to $17.1 million in the fourth quarter of 2020. GAAP net income was $13.8 million in the fourth quarter of 2021, compared to $12.7 million in the fourth quarter of 2020. GAAP diluted earnings per share (“EPS”) was $0.38 in the fourth quarter of 2021, compared to $0.35 in the fourth quarter of 2020. The Company ended the fourth quarter of 2021 with 35.8 million diluted weighted average shares outstanding.

Adjusted Diluted EPS was $0.67 in the fourth quarter of 2021, compared to $0.53 in the fourth quarter of 2020. Adjusted EBITDA was $42.6 million in the fourth quarter of 2021, compared to $32.4 million in the fourth quarter of 2020.

Operating cash flow for the fourth quarter of 2021 was $28.7 million, compared to $46.6 million for the fourth quarter of 2020.

Full Year

For the full year 2021, Novanta generated GAAP revenue of $706.8 million, an increase of $116.2 million, or 19.7%, versus the full year 2020. The Company’s acquisition activities resulted in an increase in revenue of $43.2 million, or 7.3%. Changes in foreign currency exchange rates year over year favorably impacted our revenue by $12.5 million, or 2.1%, in 2021. Our year-over-year Organic Revenue Growth, which excludes the net impact of acquisitions and changes in foreign currency exchange rates, was an increase of 10.3% for the full year 2021 (see “Organic Revenue Growth” in Reconciliation of GAAP to Non-GAAP Financial Measures below).

For the full year 2021, GAAP operating income was $64.1 million, compared to $55.9 million for 2020. GAAP net income was $50.3 million for the full year 2021, compared to $44.5 million for 2020. GAAP diluted EPS was $1.41 for the full year 2021, compared to $1.25 for 2020.

Adjusted Diluted EPS was $2.62 for the full year 2021, compared to $1.95 for 2020. Adjusted EBITDA was $152.7 million for the full year 2021, compared to $121.0 million for 2020.

Operating cash flow for the full year 2021 was $94.6 million, compared to $140.2 million for 2020. The Company finished the year with approximately $434.5 million of total debt and $117.4 million of total cash. Net Debt, as defined in Reconciliation of GAAP to Non-GAAP Financial Measures below, was $321.2 million.

Financial Outlook

“We remain extremely excited about the growth opportunities in the medical and advanced industrial sectors that we serve,” said Matthijs Glastra, “We enter 2022 with a record backlog and good visibility to customer demand for the whole year. However, we are experiencing near-term raw material shortages and disruptions, and cost inflation in our supply chain, but we will continue to work to mitigate these impacts over the course of the year as we had during the second half of 2021.”

For the first quarter of 2022, the Company expects GAAP revenue to be in the range of approximately $192 million to $200 million. The Company expects Adjusted Gross Profit Margin to be approximately 44.5%. The Company expects Adjusted EBITDA to be in the range of $38 million to $41 million and Adjusted Diluted EPS to be in the range of $0.60 to $0.66. The Company’s guidance assumes no significant changes in foreign exchange rates.

For the full year 2022, the Company expects GAAP revenue to be in the range of approximately $825 million to $845 million. The Company expects Adjusted Gross Profit Margin to be approximately 46.0%. The Company expects Adjusted EBITDA to be in the range of $172 million to $182 million and Adjusted Diluted EPS to be in the range of $2.85 to $3.00. The Company’s guidance assumes no significant changes in foreign exchange rates.

Novanta provides earnings guidance on a non-GAAP basis and does not provide earnings guidance on a GAAP basis, with the exception of GAAP revenue guidance. A reconciliation of the Company’s forward-looking Adjusted Gross Profit Margin, Adjusted EBITDA and Adjusted EPS guidance to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including future changes in the fair value of contingent considerations; significant discrete income tax expenses (benefits); divestitures and related expenses; acquisitions and related expenses; impact of purchase price allocations for recently completed acquisitions; gains and losses from sale of real estate assets; costs related to product line closures; intangible asset impairment charges and related asset write-offs; future restructuring expenses; foreign exchange gains/(losses); benefits or expenses associated with the completion of tax audits; and other charges reflected in the Company’s reconciliation of historical non-GAAP financial measures, the amounts of which, based on past experience, could be material. For additional information regarding Novanta’s non-GAAP financial measures, see “Use of Non-GAAP Financial Measures” below.

Conference Call Information

The Company will host a conference call on Tuesday, March 1, 2022 at 10:00 a.m. ET to discuss these results and to provide a business update. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com.

A replay of the audio webcast will be available approximately three hours after the conclusion of the call on the Investors section of the Company’s website at www.novanta.com. The replay will remain available until Monday, April 4, 2022.

Use of Non-GAAP Financial Measures

The non-GAAP financial measures used in this press release are Organic Revenue Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income and Operating Margin, Adjusted Income before Income Taxes, Adjusted Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Consolidated Net Income, Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow as a Percentage of Consolidated Net Income, and Net Debt.

The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Company. It is management’s belief that these non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company’s day-to-day business in accordance with the execution of the Company’s strategy. This strategy includes streamlining the Company’s existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company’s business through significant internal investments, and broadening the Company’s product and service offerings through acquisition of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company’s overall financial performance and can adversely affect the comparability of its operating results and investors’ ability to analyze the business from period to period.

The Company’s Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Profit Margin are used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Profit Margin are used to determine bonus payments for senior management and employees. The Company also uses Adjusted Diluted EPS as a measurement for performance-based restricted stock units issued to certain executives. Accordingly, the Company believes that these non-GAAP financial measures provide greater transparency and insight into management’s method of analysis.

Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

Safe Harbor and Forward-Looking Information

Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “could,” “should,” “plan,” “aim,” and other similar expressions. These forward-looking statements include, but are not limited to, statements regarding anticipated financial performance and financial position, including our financial outlook for the first quarter and full year 2022; statements regarding the COVID-19 pandemic; expectations for our end markets and market position; expectations regarding the performance from the recent ATI and IMS acquisitions; expectations for strong demand generation from our innovation; expectations for continued robust market demand; our optimism as we enter the new year, even as we navigate the near-term disruptions caused by the global supply chain shortages and widespread cost inflation; expectations regarding our design win and customer order activities and long-term prospects in our medical and advanced industrial end-markets; and other statements that are not historical facts.

These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and level of business activities; risks associated with the COVID-19 pandemic and other events outside our control; our dependence upon our ability to respond to fluctuations in product demand; our ability to continually innovate, introduce new products timely, and successfully commercialize our innovations; customer order timing and other similar factors beyond our control; disruptions or breaches in security of our and our third-party providers’ information technology systems; our failure to comply with data privacy regulations; changes in interest rates, credit ratings or foreign currency exchange rates; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; negative effects on global economic conditions, financial markets and our business as a result of the United Kingdom’s withdrawal from the European Union; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities and disruptions to our operations as a result of consolidation of our operations; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components or other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to excess inventories or delays in the delivery of our products; production difficulties and product delivery delays or disruptions; our exposure to medical device regulations, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products; potential penalties for violating foreign, U.S. federal, and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations affecting our business or products; our failure to implement new information technology systems and software successfully; our failure to realize the full value of our intangible assets; increasing scrutiny and changing expectations from investors, customers, and governments with respect to Environmental, Social and Governance policies and practices; our exposure to the credit risk of some of our customers and in weakened markets; our reliance on original equipment manufacturer customers; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws, and fluctuations in our effective tax rates; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future.

Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as updated by our future filings with the Securities and Exchange Commission (“SEC”). Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law.

About Novanta

Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in photonics, vision, and precision motion with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers’ demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”

More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 or InvestorRelations@novanta.com.

Contacts

Novanta Inc.
Investor Relations Contact:

Ray Nash

(781) 266-5137

Read full story here